Discovery of a Potent and Orally Bioavailable Keap1–Nrf2 PPI Inhibitor

Please copy the URL and add it into your RSS Feed Reader.

Facebook X Linkedin Weibo

Download PDF

Synfacts 2023; 19(09): 0934
DOI: 10.1055/s-0042-175250

Innovative Drug Discovery and Development

Contributor(s):

Antonia F. Stepan (Roche)

,

Thomas R. Puleo (Pfizer)

chronic kidney disease - noncovalent inhibitor - Keap1 - Nrf2

Article published online:
16 August 2023

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany